

JC10 Rec'd PCT/PTO 04 NOV 2005

PATENT

ATTORNEY DOCKET NO. 50026/055001

Certificate of Mailing: Date of Deposit: November 2, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Janet D'Annunzio-Ellis
Printed name of person mailing correspondence

Janet D'Annunzio-Ellis
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Sueishi et al.	Art Unit:	Not Yet Assigned
Serial No.:	10/549,474	Examiner:	Not Yet Assigned
Filed:	September 14, 2005	Customer No.:	21559
Title:	METHODS OF TREATING INFLAMMATORY DISEASES ASSOCIATED WITH BONE DESTRUCTION		

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications and as indicated below.

The present application is the U.S. national stage of PCT/JP2004/002887. A copy of the corresponding International Search report was submitted in the present application on September 14, 2005. Under M.P.E.P. (Eighth Edition, August 2001 (Revision 3, August 2005)) § 1893.03(g), Applicants note that because the International Search for PCT/JP2004/002887 was conducted by the Japanese Patent Office, copies of the

documents cited in the International Search Report should have been provided to the U.S.P.T.O. Therefore, copies of the following references are not enclosed.

JP 7-265079 A;

JP 2000-229883 A;

JP 2002-500623 A;

JP 2003-503313 A.


JP 7-265079 A, JP 2000-229883 A, JP 2002-500623 A, and JP 2003-503313 A are written in the Japanese language. The Examiner is directed to the previously submitted English language International Search Report for an explanation of relevance of these references under 37 C.F.R. § 1.98(a)(3).

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office Action on the merits. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 2 November 2005



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

JAN N. TITTEL, Ph.D.
Reg. No. 52,290

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Attorney Docket No. 50026/055001 Serial No. 10/549,474 Applicant Sueishi et al. Filing Date September 14, 2005 Group Not Yet Assigned IDS Filed November 2, 2005		
U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,060,275	May 9, 2000	Hacohen et al.			
	6,599,912	July 29, 2003	Au et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0545343	June 9, 1993	EPO			
	JP 7-265079	October 17, 1995	JPO			No
	JP 2000-229883	August 22, 2000	JPO			No
	JP 2002-500623	January 8, 2002	JPO			No
	JP 2003-503313	January 28, 2003	JPO			No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Bathon et al., "A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis," <i>N. Engl. J. Med.</i> 343(22):1586-1593 (2000).					
	Casci et al., "Sprouty, an Intracellular Inhibitor of Ras Signaling," <i>Cell</i> 96(5):655-665 (1999).					
	Charles et al., "Regulation of Cytokines, Cytokine Inhibitors, and Acute-Phase Proteins Following Anti-TNF- α Therapy in Rheumatoid Arthritis," <i>J. Immunol.</i> 163(3):1521-1528 (1999).					
	Chikazu et al., "Fibroblast Growth Factor (FGF)-2 Directly Stimulates Mature Osteoclast Function Through Activation of FGF Receptor 1 and p42/p44 MAP Kinase," <i>J. Biol. Chem.</i> 275(40):31444-31450 (2000).					
	Cohen et al., "Treatment of Rheumatoid Arthritis with Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Combination with Methotrexate," <i>Arthritis Rheum.</i> 46(3):614-624 (2002).					
	Collin-Osdoby et al., "Basic Fibroblast Growth Factor Stimulates Osteoclast Recruitment, Development, and Bone Pit Resorption in Association with Angiogenesis In Vivo on the Chick Chorioallantoic Membrane and Activates Isolated Avian Osteoclast Resorption In Vitro," <i>J. Bone Miner. Res.</i> 17(10):1859-1871 (2002).					
	Dayer and Bresnihan, "Targeting Interleukin-1 in the Treatment of Rheumatoid Arthritis," <i>Arthritis Rheum.</i> 46(3):574-578 (2002).					
	den Broeder et al., "Long Term Anti-Tumour Necrosis Factor α Monotherapy in Rheumatoid Arthritis: Effect on Radiological Course and Prognostic Value of Markers of Cartilage Turnover and Endothelial Activation," <i>Ann. Rheum. Dis.</i> 61(4):311-318 (2002).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50026/055001 10/549,474 Sueishi et al. September 14, 2005 Not Yet Assigned November 2, 2005
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
	Fürthauer et al., "Sef Is a Feedback-Induced Antagonist of Ras/MAPK-Mediated FGF Signalling," <i>Nat. Cell Biol.</i> 4(2):170-174 (2002).		
	Gross et al., "Mammalian Sprouty Proteins Inhibit Cell Growth and Differentiation by Preventing Ras Activation," <i>J. Biol. Chem.</i> 276(49):46460-46468 (2001).		
	Hacohen et al., "Sprouty Encodes a Novel Antagonist of FGF Signaling that Patterns Apical Branching of the <i>Drosophila</i> Airways," <i>Cell</i> 92(2):253-263 (1998).		
	Hanafusa et al., "Sprouty1 and Sprouty2 Provide a Control Mechanism for the Ras/MAPK Signalling Pathway," <i>Nat. Cell Biol.</i> 4(11):850-858 (2002); Advance Online Publication DOI:10.1038/ncb867 October 28, 2002.		
	Impagnatiello et al., "Mammalian Sprouty-1 and -2 Are Membrane-Anchored Phosphoprotein Inhibitors of Growth Factor Signaling in Endothelial Cells," <i>J. Cell Biol.</i> 152(5):1087-1098 (2001).		
	Kempni, "Preliminary Results of Early Clinical Trials with the Fully Human Anti-TNF α Monoclonal Antibody D2E7," <i>Ann. Rheum. Dis.</i> 58(Suppl. I):170-172 (1999).		
	Kempni, "Update on D2E7: A Fully Human Anti-Tumour Necrosis Factor α Monoclonal Antibody," <i>Ann. Rheum. Dis.</i> 59(Suppl. I):i44-i45 (2000).		
	Kramer et al., "Sprouty: A Common Antagonist of FGF and EGF Signaling Pathways In <i>Drosophila</i> ," <i>Development</i> 126(11):2515-2525 (1999).		
	Lipsky et al., "Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis," <i>N. Engl. J. Med.</i> 343(22):1594-1602 (2000).		
	Lu et al., "Vascular Endothelial Growth Factor Expression and Regulation of Murine Collagen-Induced Arthritis," <i>J. Immunol.</i> 164(11):5922-5927 (2000).		
	Maini et al., "Anti-Tumour Necrosis Factor Specific Antibody (Infliximab) Treatment Provides Insights into the Pathophysiology of Rheumatoid Arthritis," <i>Ann. Rheum. Dis.</i> 58(Suppl. I):i56-i60 (1999).		
	Maini et al., "Infliximab (Chimeric Anti-Tumour Necrosis Factor α Monoclonal Antibody) Versus Placebo in Rheumatoid Arthritis Patients Receiving Concomitant Methotrexate: A Randomised Phase III Trial," <i>Lancet</i> 354(9194):1932-1939 (1999).		
	Manabe et al., "Involvement of Fibroblast Growth Factor-2 in Joint Destruction of Rheumatoid Arthritis Patients," <i>Rheumatology</i> 38(8):714-720 (1999).		
	Miotla et al., "Treatment with Soluble VEGF Receptor Reduces Disease Severity in Murine Collagen-Induced Arthritis," <i>Lab. Invest.</i> 80(8):1195-1205 (2000).		
	Moreland et al., "Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein," <i>N. Engl. J. Med.</i> 337(3):141-147 (1997).		
	Nishimoto et al., "Anti-Interleukin 6 Receptor Antibody Treatment in Rheumatic Disease," <i>Ann. Rheum. Dis.</i> 59(Suppl. I):i21-i27 (2000).		
EXAMINER	DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 50026/055001 Serial No. 10/549,474 Applicant Sueishi et al. Filing Date September 14, 2005 Group Not Yet Assigned IDS Filed November 2, 2005
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
	Nossent et al., "Efficacy of Methylprednisolone Pulse Therapy Versus Infliximab in the Treatment of Severe Flares of Chronic Polyarthritis," <i>Scand. J. Rheumatol.</i> 30(6):335-339 (2001).	
	Sasaki et al., "Identification of a Dominant Negative Mutant of Sprouty That Potentiates Fibroblast Growth Factor- but not Epidermal Growth Factor-Induced ERK Activation," <i>J. Biol. Chem.</i> 276(39):36804-36808 (2001).	
	Sone et al., "Neutralization of Vascular Endothelial Growth Factor Prevents Collagen-Induced Arthritis and Ameliorates Established Disease in Mice," <i>Biochem. Biophys. Res. Commun.</i> 281(2):562-568 (2001).	
	Wakioka et al., "Spred Is A Sprouty-Related Suppressor of Ras Signalling," <i>Nature</i> 412(6847):647-651 (2001).	
	Wong et al., "Sprouty2 Attenuates Epidermal Growth Factor Receptor Ubiquitylation and Endocytosis, and Consequently Enhances Ras/ERK Signalling," <i>EMBO J.</i> 21(18):4796-4808 (2002).	
	Yamashita et al., "Fibroblast Growth Factor-2 Determines Severity of Joint Disease in Adjuvant-Induced Arthritis in Rats," <i>J. Immunol.</i> 168(1):450-457 (2002).	
	Yusoff et al., "Sprouty2 Inhibits the Ras/MAP Kinase Pathway by Inhibiting the Activation of Raf," <i>J. Biol. Chem.</i> 277(5):3195-3201 (2002).	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		